Pre-tax profit 18% above our expectations driven by.
ARR +7% y-o-y, in line with ABGSCe Cons. likely to make minor neg.
Redeye provides a comment on Alzinova’s TO3 exercise outcome, which generated SEK26.
45% organic sales, 1% EBIT margin (ABGSCe neg.) Guides for a "steady improvement" in margins for 202...
Q1: EBIT NOK 4.0m in line with ABGSCe 4.0m 2025 ambition reconfirmed Expect smaller estimate changes...
Redeye comments on Sleep Cycle's Q1 2023 report, which was relatively stable given the overall macro...
Q1 NII came in 1% above our estimate at DKK 78m while NCI came in at DKK 21m versus our estimate at ...
Cibus posted Q1 net operating income of EUR 27.6m, up 27% y/y on the back of acquisitions and 1% abo...
Gasporox beat our expectations by 34% on the top line with positive quarterly EBITDA.
Redeye provides an initial take on Enzymatica’s Q1 2023 report.
Vätgasbolaget befinner sig i tidig kommersialiseringsfas och möter redan ett stabilt flöde med affär...
Redeye provides an initial take on BONESUPPORT’s Q1 results and we note another estimate beat on sal...
Redeye provides an initial take on Sedana Medical’s Q1 results, and we are glad to see our estimates...
Gapwaves' report came in weaker than expected with sales decreasing 16%.
Redeye comments on Evolution’s Q1-results which came in stronger than expected with revenue slightly...
Redeye states that the Q1 report came in slightly above its estimates.
Redeye makes minor adjustments to the base case following SSH Communication Security’s Q1 2023 repor...
Redeye provides a preview of Thunderful Group ahead of its Q1 2023 report, due on May 16.
Redeye adjusts our growth assumptions slightly for 2023e and beyond.
The total subscription of 83% is in line with Redeye’s expectations.
